MDMA-Assisted Psychotherapy Training Program
Training Program
Live
Jan 01, 2024
Unknown
Vancouver, BC
Description
On September 25th, TheraPsil announced the launch of a MDMA-Assisted Psychotherapy Training Program. This groundbreaking training expansion represents a monumental leap forward in our mission to provide safe, legal, and effective therapies for individuals grappling with mental health challenges.
Why This Matters
Our expansion into MDMA-assisted psychotherapy training signifies a new chapter of growth and innovation for TheraPsil. We are broadening our advocacy efforts to encompass both psilocybin and MDMA therapies, furthering our commitment to helping patients in medical need gain legal access to psychedelic-assisted psychotherapy through Health Canada’s SAP program.
The Pilot Phase - Led by Dr. Ingrid Pacey
We invite you to apply for the pilot phase of this program, set to launch in February 2024. Dr. Ingrid Pacey, a distinguished TheraPsil trainer renowned for her role as the Principal Investigator of the MAPS Phase 2 MDMA trial in Vancouver, will lead this program. Dr. Pacey’s expertise underscores our dedication to providing top-tier training.
The pilot phase will be open to practitioners who have successfully completed the didactic portion (up to Unit 10) of TheraPsil’s Fundamentals of Psilocybin-Assisted Psychotherapy training program. However, we encourage all interested and eligible practitioners to apply to stay informed about the training offering as we transition out of the beta phase.
ENTRANCE REQUIREMENTS
Completion (Units 1-10) of TheraPsil’s Fundamentals of Psilocybin-Assisted Psychotherapy training program.
A medical degree (MD, RN), or a graduate degree (MA, PhD) in psychology, counseling psychology, or a closely related field such as psychiatric social work, psychiatric nursing or occupational therapy with psychotherapy license.
Current good standing as a professional member of a provincial clinical counseling or psychotherapy association having a Code of Ethics and a disciplinary body.* Preference will be given to applicants who already have some personal or professional psychedelic experience.
Why This Matters
Our expansion into MDMA-assisted psychotherapy training signifies a new chapter of growth and innovation for TheraPsil. We are broadening our advocacy efforts to encompass both psilocybin and MDMA therapies, furthering our commitment to helping patients in medical need gain legal access to psychedelic-assisted psychotherapy through Health Canada’s SAP program.
The Pilot Phase - Led by Dr. Ingrid Pacey
We invite you to apply for the pilot phase of this program, set to launch in February 2024. Dr. Ingrid Pacey, a distinguished TheraPsil trainer renowned for her role as the Principal Investigator of the MAPS Phase 2 MDMA trial in Vancouver, will lead this program. Dr. Pacey’s expertise underscores our dedication to providing top-tier training.
The pilot phase will be open to practitioners who have successfully completed the didactic portion (up to Unit 10) of TheraPsil’s Fundamentals of Psilocybin-Assisted Psychotherapy training program. However, we encourage all interested and eligible practitioners to apply to stay informed about the training offering as we transition out of the beta phase.
ENTRANCE REQUIREMENTS
Completion (Units 1-10) of TheraPsil’s Fundamentals of Psilocybin-Assisted Psychotherapy training program.
A medical degree (MD, RN), or a graduate degree (MA, PhD) in psychology, counseling psychology, or a closely related field such as psychiatric social work, psychiatric nursing or occupational therapy with psychotherapy license.
Current good standing as a professional member of a provincial clinical counseling or psychotherapy association having a Code of Ethics and a disciplinary body.* Preference will be given to applicants who already have some personal or professional psychedelic experience.
